IQ-AI Announce FDA ‘Clearance to Market’ For StoneChecker Software
Imaging Biometrics, IQ-AI’s Milwaukee based subsidiary, today received notification that the FDA has cleared StoneChecker Software for marketing in the USA.
David Smith, Chief Executive of the operating subsidiaries of IQ-AI stated, “We are delighted that after an exhaustive review of the product, that the FDA has cleared the product for marketing in the USA.”
A further announcement will be issued in the next few days, outlining the scale of the market opportunity for the product in the USA and IQ-AI’s plans for introduction.
The Directors of the Company accept responsibility for the contents of this announcement.
-ENDS-
